Business Context and Reporting Period
This Form 8-K filing by NantKwest, Inc. (not Immunitybio, Inc.) reports a material event occurring on June 24, 2020. The company, incorporated in Delaware and trading on the Nasdaq Global Select Market under the symbol "NK," entered into an underwriting agreement for a public offering of common stock.
Key Financial Metrics and Offering Details
- Shares Issued: 7,410,000 shares of common stock.
- Public Offering Price: $9.50 per share.
- Underwriter Purchase Price: $8.93 per share for 3,700,000 shares.
- Affiliated Purchase: Dr. Patrick Soon-Shiong (Chairman, CEO, and principal stockholder) purchased 3,710,000 shares at $12.12 per share (market value), with underwriters purchasing these from the company at $11.8776 per share.
- Net Proceeds: Approximately $76.4 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 1,111,500 additional shares at $9.50 per share.
Material Changes and Use of Proceeds
The filing details a significant capital raise intended to bolster the company's financial position. The net proceeds are designated for clinical development, manufacturing, facility and equipment upgrades, working capital, capital expenditures, and general corporate purposes. The closing of the offering was expected on or about June 29, 2020.
Management Commentary, Risks, and Contingencies
- Lock-Up Agreements: Certain officers, directors, and their affiliated entities entered into 90-day lock-up agreements prohibiting the sale or transfer of company securities, subject to exceptions.
- Legal Framework: The offering is made pursuant to an effective Form S-3 registration statement. The Underwriting Agreement includes customary representations, warranties, indemnification obligations, and termination provisions.
- Limitations: The filing notes that representations and warranties were made solely for the benefit of the parties to the agreement and may be subject to limitations.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received, as the filing states expectations as of June 24, 2020.
- Confirm whether the underwriters exercised the 30-day option to purchase the additional 1,111,500 shares.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific termination conditions and indemnification details.
- Monitor the company's cash burn rate and progress on clinical development to assess the sufficiency of the $76.4 million in proceeds.